Salazosulfapyridine (SASP) is used frequently to treat RA. Gastrointestinal disorders and rash are common adverse effects, but less is frequent is cytopenia.
Introduction
Salazosulfapyridine (SASP) is a disease-modifying anti-rheumatic drug (DMARD) used frequently to treat rheumatoid arthritis (RA) [1] . Gastrointestinal disorders and rash are common adverse effects, but less frequent is about SASP causing cytopenia in comparison to other DMARDs. [1] [2] [3] However, there are reported cases of deaths related to SASP from infectious disease, [4] [5] multi-organ failure (MOF) [6] and cerebral hemorrhage [7] . The rheumatologist should have a high index of suspicion for cytopenia, be able to detect it as early as possible, and take measures to reduce the risk of critical illness and death. We studied seven patients with RA on SASP and performed a literature review of case studies to determine the characteristics SASP-induced cytopenia and possible means of preventing this adverse effect. 
Patients and methods

Results
Demographic and clinical data are listed in Table 1 . The patients' ages ranged from 31 to 74 years (median 70 years). All of the patients were female and two out of seven had secondary Sjögren's syndrome. The time from the start of SASP to the diagnosis of cytopenia ranged from 9 days to 50 days in most patients, with one patient developing cytopenia after 383 days. The starting dosage of SASP was 500 mg per day in all patients. The dose of SASP was 1000 mg per day in all but one patient, and the medication was effective in treating RA in all patients. Other adverse effects were pyrexia (in five patients);
gastrointestinal symptoms of nausea, vomiting, epigastric pain and anorexia (in four patients); upper respiratory tract infection (in two patients) and rash (in two patients). Especially, pyrexia and upper respiratory tract infection were major symptom of lymphopenia. Leukopenia and, more often, lymphopenia were seen in all cases. Atypical lymphocytes were seen in three patients. Most patients had a baseline anemia, thought to be from chronic disease (i.e., RA), but only one patient (#4) had a decrease in hemoglobin associated with the use of SASP.
C-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) increased in all patients at the onset of cytopenia. Only two out of six patients tested had a positive drug lymphocyte stimulating test (DLST). Of the five patients who had bone marrow aspiration, three had hypo cellular marrow and two had normocellular marrow. No abnormalities in erythroblasts were observed in bone marrow aspirates. In all patients with cytopenia, SASP was stopped and in three patients granulocyte colony-stimulating factor (G-CSF) and antibiotics were administered. Six out of seven patients recovered from cytopenia after 5-8 days, and one patient died of sepsis due to Pseudomonas aeruginosa.
Discussion
SASP was originally proposed as a treatment for RA because of its anti-inflammatory and antimicrobial activities. (Table 2) . [7] In this study, all patients were female, as were all but two of the patients in previously reported case studies. [12] [13] Even though RA is more common in women than men, the higher incidence of cytopenia may related to SASP in women is thought to reflect a gender-related risk. . Most of the patients developed cytopenia within 70 days of starting SASP. However, one must remain vigilant about the appearance of this side effect even after considerable time, as one patient developed it after 300 days.
For most of the patients in this study, the dose of SASP at which cytopenia developed was 1000 mg per day. In this study, this is the dose at which the medication initially becomes effective in treating our patients with RA. Thus, it is important to watch for the development of cytopenia even at the lowest effective dose. Many of the patients had fever at the onset of cytopenia, both with and without a concurrent infection.
As in previous reports, many of the patients in this study had gastrointestinal side effects from SASP, including nausea, vomiting, epigastric pain, and anorexia.
Upper respiratory tract infection developed and was associated with leukopenia, and thus thought to be related to SASP. This infection resolved with antibiotics.
Skin rash was seen and resolved completely a few days after discontinuation of SASP.
Lymphopenia is a known adverse effect of SASP and was seen in all the patients in this study. In all but one patient with lymphopenia, the medication was stopped, and, in all cases, the lymphopenia resolved. There were no significant decreases in hemoglobin levels (below a baseline of anemia of chronic disease due to RA), except in one patient (Patient 4).
Patient 4 also developed a marked thrombocytopenia, but the other patients maintained normal platelet counts. Based on the results of bone marrow aspiration, the presumed mechanism of SASP-induced cytopenia was thought to be impairment in bone marrow production, and suppression of hemocyte generation. However, in different patients this disorder affected different cell lines, including granulocytes (most often), megakaryocytes, and erythroblasts. From these results, cytopenia due to SASP may be caused by a mechanism different from myelodysplasia syndrome (MDS). In addition, a DLST was positive in only 2 of 6 patients and the cytopenia was probably not caused by only an allergic mechanism. N-acetyltransferase 2 (NAT2) gene polymorphism is reported to relate severe adverse event of SASP.
But in this study, NAT2 gene polymorphism was not examined.
In most patients the cytopenia resolved as a result of merely discontinuing the medication. However, three patients with infections were treated with antibiotics and G-CSF together; two of these patients recovered and one, whose cytopenia was severe and had decreased IgG levels, died of sepsis. 
Conclusions
Cytopenia due to SASP in RA was observed only in female patients whose treatment was effective. Lymphopenia, atypical lymphocytes and a decrease of immunoglobulin level were seen on laboratory tests. In bone marrow aspiration, hypo cellular marrow, mainly affecting granulocytes, was seen. If detected early, cytopenia may be reversible with immediate discontinuation of SASP. However, extreme vigilance is necessary, as an infectious disease in a critically-ill patient with such cytopenia can be fatal.
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